Alkermes
Other
Active
Dublin, Ireland
11
33M
10
0.92
9
0.09
2
- Areas of investment
Summary
Alkermes appeared to be the Corporate Investor, which was created in 2011. The main department of described Corporate Investor is located in the Waltham. The company was established in North America in United States.
Among the various public portfolio startups of the fund, we may underline Civitas Therapeutics For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Therapeutics, Biotechnology.
The top activity for fund was in 2014. The increased amount of exits for fund were in 2014. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The typical case for the fund is to invest in rounds with 9 participants. Despite the Alkermes, startups are often financed by Longitude Capital, Canaan Partners, RA Capital Management. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Longitude Capital, Fountain Healthcare Partners. In the next rounds fund is usually obtained by Wellington Management, Sofinnova Investments, Rock Springs Capital.
The current fund was established by Floyd Bloom, John Clarke, Paul Schimmel.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 11
- Lead investments
- 9
- Exits
- 2
- Rounds per year
- 0.92
- Follow on index
- 0.09
- Investments by industry
- Non Profit (8)
- Therapeutics (3)
- Life Science (2)
- Biotechnology (2)
- Biopharma (2) Show 15 more
- Investments by region
-
- Ireland (1)
- United States (9)
- Peak activity year
- 2023
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 32
- Avg. valuation at time of investment
- 52M
- Group Appearance index
- 0.18
- Avg. company exit year
- 5
- Avg. multiplicator
- 4.30
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Civitas Therapeutics | 25 Aug 2014 | Biotechnology, Life Science, Therapeutics, Biopharma | Late Stage Venture | 55M | United States, Massachusetts, Chelsea |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.